Navigation Links
New Genomic Test for Coronary Artery Disease Now Available at The Heart & Vascular Center of Arizona
Date:11/17/2009

t disease and also have intermittent chest pain, so I visit Dr. Grossman yearly to assess my heart's health. When he offered me the opportunity to take the new Corus CAD test that would detect my risk for coronary artery disease, I jumped at the opportunity to take advantage of the latest technology. When Dr. Grossman walked me through the test's objective results, I immediately felt at ease to know for certain that I am unlikely to have obstructive CAD at this point."

CardioDx, a cardiovascular genomic diagnostics company that developed and launched Corus CAD, has initially launched the test in nine states, including: Kentucky, Maryland, Illinois, Washington, Wisconsin, Minnesota, North Carolina, Texas and Arizona. Patient access is expected to increase throughout the country in 2010 as Corus CAD's availability expands to additional regions.

About Obstructive Coronary Artery Disease (CAD)

Cardiovascular disease affects tens of millions of Americans each year and is the leading cause of death in the United States. Coronary artery disease (CAD) is a narrowing or blockage of the coronary arteries (the major blood vessels that supply the heart with blood, oxygen and nutrients) that reduces blood flow to the heart muscle. As a result of the blockage, the heart does not get enough oxygenated blood, which can often cause chest pain (angina), shortness of breath and other symptoms. A severe blockage can cause a heart attack (myocardial infarction) or even death; one of every five deaths among Americans is caused by CAD. In 2008, CAD had an estimated direct and indirect cost of over $165 billion.

About Corus CAD

Corus CAD is a clinically validated genomic test that integrates the expression levels of 23 genes and other patient characteristics to assess obstructive CAD. The test is intended to be used in an outpatient setting with clinically stable, non-diabetic patients who present with chest pain or w
'/>"/>

SOURCE Heart & Vascular Center of Arizona
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
2. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
3. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
4. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
5. Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
6. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
7. Curemark CEO Presents at Epigenomics Conference
8. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
9. Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
10. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
11. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Ill. , July 1, 2015 ... nationwide group of state and regional professional rheumatology ... survey of rheumatologists that explored perceptions of biosimilars ... on patients. Biosimilars are medicines ... biologic medicines. They are notably different from generic ...
(Date:7/1/2015)... 1, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... corporate presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief ... a business and financial update on Wednesday, July 8, 2015 ... A live audio webcast of the presentation may be ...
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... Fitzgerald Inaugural Healthcare Conference taking place in ... at Le Parker Meridien Hotel. ... overview of the Company,s business during his live presentation ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – today announced that they will welcome four new members to their industry ...
(Date:7/1/2015)... ... 2015 , ... Ormco Corporation, a leading manufacturer and provider ... for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual Damon ... in its mission to provide free quality orthodontic care to individuals with financial ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of the ... DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, commercial ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The Collaborative ... the New York Community Trust. The grant will allow CCF to improve quality of ... practices. , CCF was formed to respond to many changes in New York’s Medicaid ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... (Nov. 20, 2010) Columbia University Medical Center will ... researcher who has made important advances in understanding the ... disease. A promising young investigator at Columbia will also ... for disordered lipid metabolism in diabetes. ...
... By Madonna Behen HealthDay Reporter , FRIDAY, ... rising on U.S. college campuses, college officials are trying various ... that targeted off-campus boozing shows some promise, researchers say. ... California cut the level of heavy drinking at private parties ...
... Houston (UH) physicists are using complex computer simulations to ... malfunctioning, may cause Alzheimer,s and cancer. Margaret ... Samiotakis, a physics Ph.D. student, described their findings in ... kinase (PGK) are strongly perturbed by macromolecular crowding," published ...
... construct an online interactive world map which gives stark facts ... and following the birth of their child. Social scientists ... collaboration with the White Ribbon Alliance for Safe Motherhood and ... excess of 160,000 called ,The Atlas of Birth, which also ...
... News) -- People who develop gastroenteritis from E. coli-contaminated ... pressure, kidney problems and heart disease later in life, ... the Walkerton Health Study, which evaluated the long-term health ... (commonly known as stomach flu) in May 2000 after ...
... (HealthDay News) -- Among patients with kidney disease in ... some Hispanics, get sicker faster than whites do, researchers ... chronic kidney disease has been established," study co-author Dr. ... Francisco, said in a news release from the American ...
Cached Medicine News:Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 2Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 3Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 4Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 2Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 3Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 2Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 3Health News:Online map of maternal health to inform world leaders 2Health News:E. Coli Could Have Long Term Effect on Heart 2Health News:Race Seems to Impact Rate of Kidney Function Decline 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: